Systemic Lupus Erythematosus

PEDIATRICS ◽  
1961 ◽  
Vol 28 (1) ◽  
pp. 42-42
Author(s):  
JOHN M. CRAIG
Keyword(s):  
Systemic Lupus Erythematosus ◽  
New York ◽  
Lupus Erythematosus ◽  
Clinical Laboratory ◽  
Disease Process ◽  
Systemic Lupus ◽  
Long Term Follow Up ◽  
History Of ◽  
Laboratory Examinations

This small but easily read book is a carefully documented summary of the clinical, laboratory and necropsy experience at the Presbyterian Hospital in New York City in 200 cases of systemic lupus erythematosus during a 20-year period. The disease process is presented according to manifestations in individual organs and laboratory examinations. This approach emphasizes the role of the disease as one of the "great imitators" of medicine, along with syphilis, tuberculosis and malaria. Of great value are the careful observations and long-term follow-up of these patients, which gives a genuine picture of the natural history of the disease, one of the stated aims of the author.

History of systemic lupus erythematosus

2016 ◽  
Author(s):  
Manuel F. Ugarte-Gil ◽  
Graciela S. Alarcón
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Familial Aggregation ◽  
English Literature ◽  
Tenth Century ◽  
Immunosuppressive Drugs ◽  
Systemic Lupus ◽  
History Of ◽  
Definition Of

The first description of cutaneous ulcerations consistent with systemic lupus erythematosus (SLE) has been attributed to Hippocrates. The term lupus first appeared in English literature in the tenth century. Until the nineteenth century, however, this term was used to describe different conditions. Osler first recognized that organ involvement may occur with or without skin involvement. With the discovery of LE cells and autoantibodies, the use of lupus murine models, and the recognition of familial aggregation and the importance of genetic factors, the pathogenesis of SLE started to be unravelled and allowed the definition of classification criteria. In parallel, the discovery of cortisone, the use of immunosuppressive drugs and antimalarials, the control of hypertension, and the availability of renal replacement therapy improved the prognosis of SLE from a 4-year survival of 51% to a 5-year survival >90%. Advances in genetics and targeted therapies will lead to better intermediate and long-term outcomes.

scholarly journals B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response

2007 ◽  
Vol 66 (9) ◽  
pp. 1259-1262 ◽  
Author(s):  
K. P Ng ◽  
G. Cambridge ◽  
M. J Leandro ◽  
J. C W Edwards ◽  
M. Ehrenstein ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
B Cell ◽  
Lupus Erythematosus ◽  
Cell Depletion ◽  
B Cell Depletion ◽  
Systemic Lupus ◽  
Predictors Of Response ◽  
Long Term Follow Up

scholarly journals Adverse events and efficacy of TNF-  blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients

Rheumatology ◽  
2009 ◽  
Vol 48 (11) ◽  
pp. 1451-1454 ◽  
Author(s):  
M. Aringer ◽  
F. Houssiau ◽  
C. Gordon ◽  
W. B. Graninger ◽  
R. E. Voll ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Adverse Events ◽  
Lupus Erythematosus ◽  
Systemic Lupus ◽  
Long Term Follow Up

Application of SLICC classification criteria in undifferentiated connective tissue disease and evolution in systemic lupus erythematosus: analysis of a large monocentric cohort with a long-term follow-up

Lupus ◽  
2016 ◽  
Vol 26 (6) ◽  
pp. 616-622 ◽  
Author(s):  
A Bortoluzzi ◽  
F Furini ◽  
F Campanaro ◽  
M Govoni
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Connective Tissue ◽  
Lupus Erythematosus ◽  
Classification Criteria ◽  
Undifferentiated Connective Tissue Disease ◽  
Systemic Lupus ◽  
Acr Criteria ◽  
Long Term Follow Up

Objectives The objectives of this study were to analyse the performance of the Systemic Lupus International Collaborating Clinics (SLICC) 2012 classification criteria for systemic lupus erythematosus (SLE) in a large cohort of undifferentiated connective tissue disease (UCTD) population at onset of the disease and during a long-term follow-up of 15 years (1999–2013) and to evaluate the transition from UCTD to SLE, according to American College of Rheumatology (ACR) 1997 and SLICC 2012 classification criteria. Methods A cohort of patients who met the classification criteria proposed by Mosca et al. for UCTD, were analysed. The SLICC 2012 classification criteria for SLE were retrospectively applied to each patient at the time of the diagnosis (T0) and also periodically re-applied and compared to ACR 1997 criteria at three different time points in the follow-up. Results 329 patients were enrolled. According to inclusion criteria at T0 no patient met the SLE/ACR criteria, whilst, retrospectively applying the SLE/SLICC criteria, 44 patients already satisfied this set of criteria for SLE. During the follow-up 23 new patients reached the SLE/SLICC criteria and 14 patients met the ACR criteria with a stable rate of progression to SLE over time. Acute or subacute skin rash, antiphospholipid antibody (aPL) positivity and serositis were the variables correlated to the evolution to SLE. Conclusions In our UCTD population, the application of SLICC classification criteria for SLE at disease onset allowed identification of a proportion of otherwise missed SLE cases; during follow-up, and compared with ACR criteria, SLICC criteria expanded the number of patients classifiable as SLE otherwise classified as UCTD.

Sign in / Sign up

Export Citation Format

Share Document